Kymera officer plans sale of 6,371 shares
Officer Brian Adams filed a Form 144 to sell 6,371 Kymera shares from recently vested RSUs to cover tax withholding obligations.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kymera Therapeutics, Inc. (KYMR) is the issuer for a Form 144 notice filed for the potential sale of up to 6,371 shares of its common stock for the account of officer Brian Adams. The shares were acquired on September 3, 2026 upon vesting of Restricted Stock Units under Kymera’s 2020 Equity Incentive Plan.
The notice states that the sales are intended to cover tax withholding obligations related to the RSU vesting, will be executed through Morgan Stanley Smith Barney LLC, and were automatic transactions intended to qualify under Rule 10b5-1.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
Rule 10b5-1 regulatory
Equity Incentive Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Kymera Therapeutics (KYMR) disclose in this Form 144 filing?
What type of security is being sold in the Kymera (KYMR) Form 144 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.